Literature DB >> 16490598

A t(12;17)(p13;q12) identifies a distinct TEL rearrangement-negative subtype of precursor-B acute lymphoblastic leukemia.

Alistair G Reid1, Leea Seppa, Nicolas von der Weid, Felix K Niggli, David R Betts.   

Abstract

Structural rearrangements involving the short arm of chromosome 12 are common in acute lymphoblastic leukemia (ALL) and often involve the TEL locus at 12p13. The balanced t(12;17)(p13;q12) is a rare but recurrent aberration in ALL. Whereas the TEL gene has been postulated as a likely candidate for involvement in the t(12;17), the precise molecular consequences of this translocation have not yet been elucidated. We identified a t(12;17) in 2 of 398 childhood ALL patients karyotyped at presentation in our institute. Both cases had a precursor-B immunophenotype and were CD10 negative and CD33 positive. Fluorescence in situ hybridization excluded involvement of the TEL locus in the t(12;17) and provided no evidence for concomitant cryptic deletion of the 12p commonly deleted region. Comparison of these and previously published cases demonstrates that the translocation predominately occurs in children and young adults with precursor B-ALL and is typically characterized by low CD10 expression and high CD33 expression. Our data support the involvement of a new locus telomeric to TEL in the pathogenesis of t(12;17)-positive ALL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16490598     DOI: 10.1016/j.cancergencyto.2005.07.007

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  2 in total

Review 1.  An Adult Patient with Early Pre-B Acute Lymphoblastic Leukemia with t(12;17)(p13;q21)/ZNF384-TAF15.

Authors:  Nikolaos Georgakopoulos; Panagiotis Diamantopoulos; Francesca Micci; Nefeli Giannakopoulou; Konstantinos Zervakis; Aglaia Dimitrakopoulou; Nora-Athina Viniou
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

2.  t(12;17)(p13;q12)/TAF15-ZNF384 Rearrangement in Acute Lymphoblastic Leukemia.

Authors:  Jieun Kim; Hyo Sun Kim; Saeam Shin; Seung Tae Lee; Jong Rak Choi
Journal:  Ann Lab Med       Date:  2016-07       Impact factor: 3.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.